‘Mirikizumab’ a monoclonal antibody is now approved for treating moderate -severe Crohn’s disease.In a double blind,randomised controlled trial, the drug proved to be effective and safe for patients who did not respond well to other biologic treatments.
3 Likes
It’s a good news
1 Like